BioProspect announced that the active ingredient in Termilone, erimophilone oil, had gained regulatory approval in Australia.
BioProspect announced that the active ingredient in Termilone, Erimophilone Oil, had gained regulatory approval in Australia.
BioProspect Managing Director Charles Pellegrino, said the decision by the Australian Pesticides and Veterinary Medicines Authority (APVMA) to register Erimophilone Oil as a “technical grade active constituent” paved the way for registration of end-user products.
“This decision by the APVMA is a major achievement for BioProspect and its team of scientific and commercial collaborators, including the CSIRO, the University of Western Sydney (UWS) and Southern Cross University (SCU). “It is the culmination of a process that started in 2003 with the discovery of the termite-resistant properties of oil extracted from the native Australian tree species Eremophila mitchellii (False Sandalwood), followed by extensive laboratory and field trials and the submission of a data package to the authority in October 2008.”
Pellegrino added, “Active constituent registration will facilitate the registration of end-user products in the Australian market, and ultimately in the world’s largest termite control markets of the United States and Japan.”
Pellegrino said the company anticipated achieving the registration of end-user products with the APVMA within the next two years, due to the need for additional data from field trials and the expected time required to achieve regulatory approval.